Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity

Nature Biotechnology

Volumn 15, Issue 2, 1997, Pages 155-158

  Magliani, W ^a   Conti, S ^a   De Bernardis, F ^b   Gerloni, M ^a   Bertolotti, D ^a   Mozzoni, P ^a   Cassone, A ^b   Polonelli, L ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Experimental vaginitis; Fungicidal peptides; Recombinant antiidiotypic antibodies; Therapeutic treatment; Yeast killer toxin

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; IDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; TOXIN;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CANDIDA ALBICANS; DNA RECOMBINATION; DRUG ACTIVITY; DRUG SYNTHESIS; FUNGICIDAL ACTIVITY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; DNA, RECOMBINANT; DRUG DESIGN; FEMALE; GENETIC ENGINEERING; IMMUNOTOXINS; MICE; MICROBIAL SENSITIVITY TESTS; MYCOTOXINS; PICHIA; RATS;

ANIMALIA; CANDIDA ALBICANS; PICHIA ANOMALA;

EID: 0031044651     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0297-155     Document Type: Article

References (28)

1. Jerne, N.K. 1974. Towards a network theory of the immune system. Ann. Immunol. Inst. Pasteur 125C:373-389.
2. Poljak, R.J. 1994. Commentary. An idiotope-anti-idiotope complex and the structural basis of molecular mimicking. Proc. Natl. Acad. Sci. USA 91:1599-1600.
3. Gaulton, G.N. and Greene, M.I. 1986. Idiotypic mimicry of biological receptors. Annu. Rev. Immunol. 4:253-280.
4. Nisonoff, A. and Gorish, M.F. 1984. From network theory toward vaccination by monoclonal antibodies, pp. 119-128 in New Horizons in Microbiology. Sanna, A. and Morace, G. (eds.). Elsevier Science Publishers, Amsterdam.
5. Brinkmann, U. and Pastan, I. 1994. Immunotoxins against cancer. Biochim. Biophys. Acta 1198:27-45.
6. Bona, C. and Köhler, H. 1984. Antiidiotypic antibodies and internal images. Recept. Biochem. Methodol. 14:141-149.
7. Monroe, J.G. and Greene, M.I. 1986. Antiidiotypic antibodies and disease. Immunol. Invest. 15:263-286.
8. Armstrong, D. 1993. History of opportunistic infections in the immunocompromised host. Clin. Infect. Dis. 17:S318-S321.
9. Polonelli L. and Morace, G. 1987. Production and characterization of yeast killer toxin monoclonal antibodies. J. Clin. Microbiol. 25:460-462.
10. Polonelli L. and Morace, G. 1986. Reevaluation of the yeast killer phenomenon. J. Clin. Microbiol. 24:866-869.
11. Aliouat, E.M., Cailliez, J.C., Séguy, N., Dei-Cas, E., Polonelli L., et al. 1993. Inhibitory effect of a yeast killer toxin to the in vitro Pneumocystis carinii attachment. Serodiagn. Immunother. Infect. Dis. 5:102-106.
12. Polonelli L. and Morace, G. 1988. Yeast killer toxin-like antiidiotypic antibodies. J. Clin. Microbiol. 26:602-604.
13. Polonelli L., Conti, S., Gerloni, M., Magliani, W., Castagnola, M., Morace, G., and Chezzi, C. 1991. “Antibiobodies”: antibiotic-like antiidiotypic antibodies. J. Med. Vet. Mycol. 29:235-242.
14. Polonelli L., Lorenzini, R., De Bernardis, F., Gerloni, M., Conti, S., Morace, G., Magliani, W., and Chezzi, C., 1993. Idiotypic vaccination: Immunoprotection mediated by antiidiotypic antibodies with antibiotic activity. Scand. J. Immunol. 37:105-110.
15. Polonelli L., De Bernardis, F., Conti, S., Boccanera, M., Gerloni, M., Morace, G., Magliani, W., Chezzi, C., and Cassone A. 1994. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like antiidiotypic antibodies. J. Immunol. 152:3175-3182.
16. Polonelli L., Fanti, F., Conti, S., Campani, L., Gerloni, M., Castagnola, M., Morace, G., and Chezzi, C. 1990. Detection by immunofluorescent antiidiotypic antibodies of yeast killer toxin cell wall receptors of Candida albicans. J. Immunol. Methods 132:205-209.
17. Polonelli L., De Bernardis, F., Conti, S., Boccanera, M., Magliani, W., Gerloni, M., Cantelli, C., and Cassone A. 1996. Human natural yeast killer toxin-like candidacidal antibodies. J. Immunol. 156:1880-1885.
18. Barbas, C.F., Kang, A.S., Lerner, R.A., and Benkovic, S.J. 1991. Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. Proc. Natl. Acad. Sci. USA 88:7978-7982.
19. Clackson, T., Hoogenboom, H.R., Griffiths, A.D., and Winter, G. 1991. Making antibody fragments using phage display libraries. Nature 352:624-628.
20. Marks, J.D., Hoogenboom, H.R., Bonnert, T.P., McCafferty, J., Griffiths, A.D., and Winter, G. 1991. By-passing immunisation: human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-597.
21. McCafferty, J., Griffiths, A.D., Winter, G., and Chiswell, D.J. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature (London) 348:552-554.
22. Polonelli L., Séguy, N., Conti, S., Gerloni, M., Bertolotti, D., Cantelli, C., Magliani, W., and Cailliez, J.C. Monoclonal yeast killer toxin-like candidacidal antiidiotypic antibodies. Clin. Diagn. Lab. Immunol., in press.
23. Cassone A., Conti, S., De Bernardis, F., and Polonelli L. Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol. Today, in press.
24. Cutler, J.E. 1991. Putative virulence factors of Candida albicans. Annu. Rev. Microbiol. 45:187-218.
25. Cassone A., Boccanera, M., Adriani, D., Santoni, G., and De Bernardis, F. 1995. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect. Immun. 63:2619-2624.
26. Fidel, P.L., Lynch, M.E., and Sobel, J.D. 1993. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect. Immun. 61:1990-1995.
27. De Bernardis, F., Agatensi, L., Ross, I.K., Emerson, G.W., Lorenzini, R., Sullivan P.A., and Cassone A. 1990. Evidence for a role of secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J. Infect. Dis. 161:1276-1283.
28. Teti, G., Calapai, M., Calogero, G., Tomasello, F., Mancuso, G., Galli, A., and Riggio, G. 1992. Specificity and protective activity of murine monoclonal antibodies directed against the capsular polysaccharide of type III group B Streptococci. Hybridoma 11:13-22.